DK2283861T3 - Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig - Google Patents

Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig Download PDF

Info

Publication number
DK2283861T3
DK2283861T3 DK10178480.9T DK10178480T DK2283861T3 DK 2283861 T3 DK2283861 T3 DK 2283861T3 DK 10178480 T DK10178480 T DK 10178480T DK 2283861 T3 DK2283861 T3 DK 2283861T3
Authority
DK
Denmark
Prior art keywords
ivig
mlvig
itp
antibody
monoclonal
Prior art date
Application number
DK10178480.9T
Other languages
English (en)
Inventor
Alan H Lazarus
John Freedman
Seng Song
Andrew R Crow
Original Assignee
Canadian Blood Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canadian Blood Services filed Critical Canadian Blood Services
Application granted granted Critical
Publication of DK2283861T3 publication Critical patent/DK2283861T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (8)

1. Farmaceutisk sammensætning til anvendelse i behandling af autoimmun thrombocytisk purpura hos et pattedyr, hvilken sammensætning omfatter en effektiv mængde af et anti-CD44 monoklonalt antistof, der er specifikt for leukocytter, i kombination med en farmaceutisk acceptabel bærer, hvor det monoklonale antistof er i stand til at hæmme det reticuloendotheliale system (RES).
2. Farmaceutisk sammensætning ifølge krav 1, hvilken sammensætning endvidere omfatter humant IVIG.
3. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, hvor det monoklonale antistof terapeutisk øger og bevarer trombocytantallet.
4. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, hvor pattedyret er et menneske eller et dyr.
5. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, hvor antistoffet er tilpasset til intravenøs, interperitoneal, intramuskulær eller subkutan administration.
6. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, hvilken sammensætning er fri for kontaminanter såsom TGFp.
7. Anvendelse af mindst 1 pg monoklonalt antistof pr. kg legemsvægt for et pattedyr og en farmaceutisk acceptabel bærer til fremstilling af et medikament til at øge trombocytniveauet hos et pattedyr, der har autoimmun thrombocytisk purpura, hvor det monoklonale antistof er et anti-CD44 monoklonalt antistof, der er specifikt for leukocytter og i stand til at hæmme det reticuloendotheliale system (RES).
8. Mindst 1 pg monoklonalt antistof pr. kg legemsvægt for et pattedyr og en farmaceutisk acceptabel bærer til anvendelse ved øgning af niveauet af trombocytter hos et pattedyr, der har autoimmun thrombocytisk purpura, hvor det monoklonale antistof er et anti-CD44 monoklonalt antistof, der er specifikt for leukocytter og i stand til at hæmme det reticuloendotheliale system (RES).
DK10178480.9T 2000-11-20 2001-11-20 Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig DK2283861T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24944100P 2000-11-20 2000-11-20
EP01996390A EP1370288B1 (en) 2000-11-20 2001-11-20 Method for treating thrombocytopenia with monoclonal ivig

Publications (1)

Publication Number Publication Date
DK2283861T3 true DK2283861T3 (da) 2016-02-15

Family

ID=22943488

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10178480.9T DK2283861T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig
DK01996390.9T DK1370288T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK01996390.9T DK1370288T3 (da) 2000-11-20 2001-11-20 Fremgangsmåde til fremstilling af thrombocytopeni med monoklonalt IVIG

Country Status (7)

Country Link
US (1) US20040047862A1 (da)
EP (2) EP2283861B1 (da)
AT (1) ATE540694T1 (da)
AU (1) AU2002220404A1 (da)
CA (2) CA2467781C (da)
DK (2) DK2283861T3 (da)
WO (1) WO2002040047A2 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1737487B1 (en) * 2004-03-30 2016-05-25 Canadian Blood Services Method for treating autoimmune diseases with antibodies
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8597636B2 (en) 2006-01-13 2013-12-03 Canadian Blood Services Method for treating autoimmune diseases and compositions therefor
CA2647524C (en) 2006-04-05 2019-11-26 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
WO2009132130A2 (en) 2008-04-22 2009-10-29 The Rockefeller University Methods of identifying anti-inflammatory compounds
WO2014093417A1 (en) * 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
SG11201605203UA (en) 2013-12-24 2016-07-28 Argen X N V Fcrn antagonists and methods of use
CA2978253A1 (en) 2015-03-09 2016-09-15 Argenx Bvba Methods of reducing serum levels of fc-containing agents using fcrn antagonists
CA3081144A1 (en) 2017-12-08 2019-06-13 Argenx Bvba Use of fcrn antagonists for treatment of generalized myasthenia gravis
US12202900B2 (en) 2018-06-08 2025-01-21 argenx BV Compositions and methods for treating immune thrombocytopenia
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
JP7565951B2 (ja) 2019-06-07 2024-10-11 アルジェニクス ビーブイ 皮下投与に好適なＦｃＲｎインヒビターの医薬製剤
JP2023509195A (ja) 2020-01-08 2023-03-07 アルジェニクス ビーブイ 天疱瘡症を治療する方法
CN119698429A (zh) 2022-06-15 2025-03-25 阿根思有限公司 Fcrn结合分子及使用方法
GB202319605D0 (en) 2023-12-20 2024-01-31 argenx BV Monovalent binding molecules and methods of use
WO2025229206A1 (en) 2024-05-03 2025-11-06 argenx BV Monovalent anti-iga binding molecules and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993812A (en) * 1995-09-14 1999-11-30 Cangene Corporation Method of delaying the progression of an infection with the human immunodeficiency virus
JPH0987202A (ja) * 1995-09-20 1997-03-31 Sumitomo Pharmaceut Co Ltd 血液凝固異常治療剤
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
US5980893A (en) * 1997-07-17 1999-11-09 Beth Israel Deaconess Medical Center, Inc. Agonist murine monoclonal antibody as a stimulant for megakaryocytopoiesis
WO2000067796A1 (en) * 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US20030095966A1 (en) * 2000-03-29 2003-05-22 Yang Liu Method of blocking tissue destruction by autoreactive T cells
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
AUPR540301A0 (en) * 2001-06-01 2001-06-28 Walter And Eliza Hall Institute Of Medical Research, The A method of purification of cells

Also Published As

Publication number Publication date
US20040047862A1 (en) 2004-03-11
CA2467781C (en) 2014-09-23
EP1370288B1 (en) 2012-01-11
EP2283861A3 (en) 2013-05-29
ATE540694T1 (de) 2012-01-15
EP1370288A2 (en) 2003-12-17
DK1370288T3 (da) 2012-03-05
EP2283861B1 (en) 2016-01-27
CA2856033A1 (en) 2002-05-23
CA2467781A1 (en) 2002-05-23
EP2283861A2 (en) 2011-02-16
WO2002040047A2 (en) 2002-05-23
CA2856033C (en) 2015-11-03
AU2002220404A1 (en) 2002-05-27
WO2002040047A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
DK2283861T3 (da) Fremgangsmåde til behandling af trombocytopeni med monoklonalt ivig
Semple Immune pathophysiology of autoimmune thrombocytopenic purpura
Crow et al. IVIg inhibits reticuloendothelial system function and ameliorates murine passive‐immune thrombocytopenia independent of anti‐idiotype reactivity
US7662928B2 (en) Anti-FcRn antibodies for treatment of auto/allo immune conditions
Bussel et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect [see comments]
Lazarus et al. Mechanism of action of IVIG and anti-D in ITP
Debre et al. Infusion of Fcγ fragments for treatment of children with acute immune thrombocytopenic purpura
JP3616091B2 (ja) 自己免疫疾患および炎症性疾患の治療
Teeling et al. Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro
EP1986690A2 (en) ANTI-FcRn ANTIBODIES FOR TREATEMENT OF AUTO/ALLO IMMUNE CONDITIONS
van Vugt et al. Investigational drugs for the treatment of kidney transplant rejection
WO2005013912A2 (en) Anti-fcrn antibodies for treatment of auto/allo immune conditions
Bussel The use of intravenous γ-globulin in idiopathic thrombocytopenic purpura
Berger Immunoglobulin products
Bussel Novel approaches to refractory immune thrombocytopenic purpura
Dézsi et al. Intravenous immunoglobulin: pharmacological properties and use in polyneuropathies
Aledort et al. Efficacy and safety of intravenous anti-D immunoglobulin (Rhophylac®) in chronic immune thrombocytopenic purpura
Wallace et al. FcγRI blockade and modulation for immunotherapy
Sanchez-Ramon et al. Subcutaneous immunoglobulins: a promising alternative for immunomodulation?
Savasman et al. Serologic aspects of treating immune thrombocytopenic purpura using intravenous Rh immune globulin
Newland et al. Effect of intravenous immunoglobulin on a spontaneous inhibitor to factor VIII
US6749852B1 (en) Method for preventing and inhibiting human HLA alloimmune response to platelet transfusion
Durelli High-dose intravenous immunoglobulin G treatment of myasthenia gravis
DK1737487T3 (da) Fremgangsmåde til behandling af autoimmune sygdomme med antistoffer
CA3224173A1 (en) Method of administering anti-hpa-1a monoclonal antibody